Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes
Lim, Li Ying and Koh, Pei Yin and Somani, Sukrut and Al Robaian, Majed and Karim, Reatul and Yean, Yi Lyn and Mitchell, Jennifer and Tate, Rothwelle J. and Edrada-Ebel, RuAngelie and Blatchford, David R. and Mullin, Margaret and Dufès, Christine (2015) Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes. Nanomedicine: Nanotechnology, Biology and Medicine, 11 (6). pp. 1445-1454. ISSN 1549-9634 (https://doi.org/10.1016/j.nano.2015.04.006)
Preview |
Text.
Filename: 1_s2.0_S1549963415000957_main.pdf
Final Published Version License: Download (1MB)| Preview |
Abstract
The possibility of using gene therapy for the treatment of cancer is limited by the lack of safe, intravenously administered delivery systems able to selectively deliver therapeutic genes to tumors. In this study, we investigated if the conjugation of the polypropylenimine dendrimer to lactoferrin and lactoferricin, whose receptors are overexpressed on cancer cells, could result in a selective gene delivery to tumors and a subsequently enhanced therapeutic efficacy. The conjugation of lactoferrin and lactoferricin to the dendrimer significantly increased the gene expression in the tumor while decreasing the non-specific gene expression in the liver. Consequently, the intravenous administration of the targeted dendriplexes encoding TNFα led to the complete suppression of 60% of A431 tumors and up to 50% of B16-F10 tumors over one month. The treatment was well tolerated by the animals. These results suggest that these novel lactoferrin- and lactoferricin-bearing dendrimers are promising gene delivery systems for cancer therapy.
ORCID iDs
Lim, Li Ying, Koh, Pei Yin, Somani, Sukrut ORCID: https://orcid.org/0000-0002-0697-1110, Al Robaian, Majed, Karim, Reatul, Yean, Yi Lyn, Mitchell, Jennifer, Tate, Rothwelle J., Edrada-Ebel, RuAngelie, Blatchford, David R., Mullin, Margaret and Dufès, Christine ORCID: https://orcid.org/0000-0002-7963-6364;-
-
Item type: Article ID code: 52640 Dates: DateEvent31 August 2015Published29 April 2015Published Online6 April 2015AcceptedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences
Technology and Innovation Centre > BionanotechnologyDepositing user: Pure Administrator Date deposited: 14 Apr 2015 10:50 Last modified: 25 Nov 2024 03:34 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/52640